The role of percutaneous XXXX as a bridge for transcatheter aortic valve implantation.

@entity1 @entity64 @entity339 @entity2333 @entity472 @entity204
AIMS: Many inoperable @entity1 with severe @entity472 ( @entity472 ) are not immediately eligible for transcatheter aortic valve implantation (TAVI). We evaluated the role of percutaneous @entity2333 ( @entity2333 ) in this setting. METHODS AND RESULTS: Among 210 consecutive @entity1 referred to our institution for @entity2333 , we identified three groups: immediately eligible for TAVI (n=65, 31%), excluded from TAVI (n=67, 32%), @entity2333 as a bridge to TAVI (n=78, 37%). This last group comprised @entity1 with low left ventricular ejection fraction, frailty or enfeebled status, symptoms of uncertain origin, critical conditions, moderate-to-severe @entity339 , need of major non-cardiac surgery. Outpatient clinic visit and echocardiography were performed around one month after @entity2333 to decide the final therapeutic strategy. Mean age was 81  8 years and the vast majority of @entity1 had comorbidities and high-risk features. The incidence of periprocedural adverse events was 6.4%: 5.1% @entity204 (four @entity1 : one procedural complication, three, natural disease progression), 1.3% minor @entity64 . After @entity2333 , 46% of these @entity1 were deemed eligible for TAVI, and 28% for cardiac surgery. @entity1 who underwent TAVI after bridge @entity2333 showed 94% 30-day survival. CONCLUSIONS: @entity2333 is a safe and effective tool to bridge selected @entity1 to TAVI when indications are not obvious.
